메뉴 건너뛰기




Volumn 104, Issue 2, 2007, Pages 377-380

Tertiary cytoreductive surgery in recurrent ovarian cancer: Selection criteria and survival outcome

Author keywords

Cytoreductive surgery; Epithelial ovarian cancer; Recurrent disease

Indexed keywords

ANTINEOPLASTIC AGENT; PLATINUM DERIVATIVE; TAXANE DERIVATIVE;

EID: 33846375869     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2006.08.037     Document Type: Article
Times cited : (47)

References (14)
  • 1
    • 0032077205 scopus 로고    scopus 로고
    • Complete cytoreductive surgery is feasible and maximizes survival in patients with advanced epithelial ovarian cancer: a prospective study
    • Eisenkop S.M., Friedman R.L., and Wang H.J. Complete cytoreductive surgery is feasible and maximizes survival in patients with advanced epithelial ovarian cancer: a prospective study. Gynecol. Oncol. 69 (1998) 103-108
    • (1998) Gynecol. Oncol. , vol.69 , pp. 103-108
    • Eisenkop, S.M.1    Friedman, R.L.2    Wang, H.J.3
  • 2
    • 9744223515 scopus 로고    scopus 로고
    • Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma
    • Vasey P.A., Jayson G.C., Gordon A., et al. Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma. J. Natl. Cancer Inst. 96 (2004) 1682-1691
    • (2004) J. Natl. Cancer Inst. , vol.96 , pp. 1682-1691
    • Vasey, P.A.1    Jayson, G.C.2    Gordon, A.3
  • 3
    • 0141688377 scopus 로고    scopus 로고
    • Gynecologic oncology group. phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a gynecologic oncology group study
    • Ozols R.F., Bundy B.N., Greer B.E., et al. Gynecologic oncology group. phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a gynecologic oncology group study. J. Clin. Oncol. 21 (2003) 3194-3200
    • (2003) J. Clin. Oncol. , vol.21 , pp. 3194-3200
    • Ozols, R.F.1    Bundy, B.N.2    Greer, B.E.3
  • 4
    • 4644225190 scopus 로고    scopus 로고
    • Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer
    • Gordon A.N., Tonda M., Sun S., et al. Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer. Gynecol. Oncol. 95 (2004) 1-8
    • (2004) Gynecol. Oncol. , vol.95 , pp. 1-8
    • Gordon, A.N.1    Tonda, M.2    Sun, S.3
  • 5
    • 0037862963 scopus 로고    scopus 로고
    • Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial
    • Parmar M.K., Ledermann J.A., Colombo N., et al. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet 361 (2003) 2099-2106
    • (2003) Lancet , vol.361 , pp. 2099-2106
    • Parmar, M.K.1    Ledermann, J.A.2    Colombo, N.3
  • 6
    • 7444240809 scopus 로고    scopus 로고
    • Critical evaluation of secondary cytoreduction in recurrent ovarian cancer
    • Munkarah A.R., and Coleman R.L. Critical evaluation of secondary cytoreduction in recurrent ovarian cancer. Gynecol. Oncol. 95 (2004) 273-280
    • (2004) Gynecol. Oncol. , vol.95 , pp. 273-280
    • Munkarah, A.R.1    Coleman, R.L.2
  • 7
    • 0036498788 scopus 로고    scopus 로고
    • Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis
    • Bristow R.E., Tomacruz R.S., Armstrong D.K., et al. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J. Clin. Oncol. 20 (2002) 1248-1259
    • (2002) J. Clin. Oncol. , vol.20 , pp. 1248-1259
    • Bristow, R.E.1    Tomacruz, R.S.2    Armstrong, D.K.3
  • 8
    • 0027513786 scopus 로고
    • Secondary cytoreduction for ovarian cancer following cisplatin therapy
    • Segna R.A., Dottino P.R., Mandeli J.P., et al. Secondary cytoreduction for ovarian cancer following cisplatin therapy. J. Clin. Oncol. 11 (1993) 434-439
    • (1993) J. Clin. Oncol. , vol.11 , pp. 434-439
    • Segna, R.A.1    Dottino, P.R.2    Mandeli, J.P.3
  • 9
    • 0033957510 scopus 로고    scopus 로고
    • The role of secondary cytoreductive surgery in the treatment of patients with recurrent epithelial ovarian carcinoma
    • Eisenkop S.M., Friedman R.L., and Spirtos N.M. The role of secondary cytoreductive surgery in the treatment of patients with recurrent epithelial ovarian carcinoma. Cancer 88 (2000) 144-153
    • (2000) Cancer , vol.88 , pp. 144-153
    • Eisenkop, S.M.1    Friedman, R.L.2    Spirtos, N.M.3
  • 10
    • 1542344369 scopus 로고    scopus 로고
    • Secondary cytoreductive surgery for patients with relapsed epithelial ovarian carcinoma: who benefits?
    • Zang R.Y., Li Z.T., Tang J., et al. Secondary cytoreductive surgery for patients with relapsed epithelial ovarian carcinoma: who benefits?. Cancer 100 (2004) 1152-1161
    • (2004) Cancer , vol.100 , pp. 1152-1161
    • Zang, R.Y.1    Li, Z.T.2    Tang, J.3
  • 11
    • 0024439661 scopus 로고
    • Secondary cytoreductive surgery for recurrent epithelial ovarian cancer
    • Morris M., Gershenson D.M., Wharton J.T., et al. Secondary cytoreductive surgery for recurrent epithelial ovarian cancer. Gynecol. Oncol. 34 (1989) 334-338
    • (1989) Gynecol. Oncol. , vol.34 , pp. 334-338
    • Morris, M.1    Gershenson, D.M.2    Wharton, J.T.3
  • 12
    • 0033670096 scopus 로고    scopus 로고
    • Complete salvage surgical cytoreduction improves further survival of patients with late recurrent ovarian cancer
    • Gadducci A., Iacconi P., Cosio S., et al. Complete salvage surgical cytoreduction improves further survival of patients with late recurrent ovarian cancer. Gynecol. Oncol. 79 (2000) 344-349
    • (2000) Gynecol. Oncol. , vol.79 , pp. 344-349
    • Gadducci, A.1    Iacconi, P.2    Cosio, S.3
  • 13
    • 0032053575 scopus 로고    scopus 로고
    • Palliative benefit of external-beam radiation in the management of platinum refractory epithelial ovarian carcinoma
    • Gelblum D., Mychalczak B., Almadrones L., et al. Palliative benefit of external-beam radiation in the management of platinum refractory epithelial ovarian carcinoma. Gynecol. Oncol. 69 (1998) 36-41
    • (1998) Gynecol. Oncol. , vol.69 , pp. 36-41
    • Gelblum, D.1    Mychalczak, B.2    Almadrones, L.3
  • 14
    • 4644285766 scopus 로고    scopus 로고
    • Tertiary cytoreduction in patients with recurrent ovarian carcinoma
    • Leitao Jr. M.M., Kardos S., Barakat R.R., et al. Tertiary cytoreduction in patients with recurrent ovarian carcinoma. Gynecol. Oncol. 95 (2004) 181-188
    • (2004) Gynecol. Oncol. , vol.95 , pp. 181-188
    • Leitao Jr., M.M.1    Kardos, S.2    Barakat, R.R.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.